Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

August 3rd 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

PV Treatment Options and Dosing

July 28th 2021

Jamile Shammo, MD, FASCP, FACP, shares insight into the currently available treatment options for polycythemia vera and examines how treatment intolerance and/or resistance can impact the therapeutic approach.

Risk Stratification and Treatment Considerations in PV

July 28th 2021

A key opinion leader in the management of polycythemia vera discusses risk stratification and reflects on factors that influence the decision to observe or treat the patient’s disease.

Myeloproliferative Neoplasms: Diagnosing Polycythemia Vera

July 28th 2021

An expert in hematologic malignancies, Jamile Shammo, MD, FASCP, FACP, provides an overview of the 2016 WHO diagnostic criteria for polycythemia vera and considers the role of genetic testing.

Dr. Jamieson on Symptom Management in Myelofibrosis

July 21st 2021

Catriona Jamieson, MD, PhD, discusses symptom management in patients with myelofibrosis.

Dr. Kiladjian on Improving Transfusion-Independence Rates With Momelotinib in Myelofibrosis

July 21st 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the potential utility of momelotinib in improving transfusion-independence rates in myelofibrosis.

Bone Marrow Transplant for Patients With MF

July 20th 2021

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Fedratinib for Patients With Primary Myelofibrosis

July 13th 2021

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

Ruxolitinib for Patients With Primary Myelofibrosis

July 13th 2021

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

Monitoring Disease Response or Progression in MF

July 6th 2021

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Recent Updates to NCCN Guidelines on MF Treatment

July 6th 2021

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Phase 3 MOMENTUM Study Completes Enrollment in Myelofibrosis

July 1st 2021

Enrollment to the pivotal phase 3 MOMENTUM trial, which is evaluating the novel JAK1/2 and ACVR1/ALK2 inhibitor momelotinib vs danazol in patients with symptomatic myelofibrosis and anemia, has completed.

Using NGS to Inform More Than Diagnosis in Myeloid Malignancies

June 29th 2021

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

Therapeutic Decision-Making for Primary Myelofibrosis

June 29th 2021

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

Diagnosis and Prognosis of Primary Myelofibrosis

June 29th 2021

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

Dr. Mesa on the Unique Characteristics of Pacritinib in Myelofibrosis

June 24th 2021

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Dr. Kiladjian on the Potential Utility of Momelotinib in Myelofibrosis

June 21st 2021

Jean-Jacques Kiladjian, MD, PhD, discusses, the potential utility of momelotinib in myelofibrosis.

Transfusion Independence With Momelotinib Confers Benefit Regardless of Baseline Factors in Myelofibrosis

June 18th 2021

Achieving transfusion independence after 24 weeks of treatment with momelotinib is associated with clinical benefit in patients with myelofibrosis irrespective of the degree of anemia, platelet count, or transfusion status at baseline.

Dr. Mascarenhas on Potential for Pacritinib to Address an Unmet Need in Myelofibrosis

June 17th 2021

John O. Mascarenhas, MD, discusses the potential for pacritinib to address an unmet need in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Efficacy of Pacritinib in Myelofibrosis

June 17th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.